FILTER
FILTERED ARTICLE RESULTS
Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals
October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich
Arizona Copper Production: Securing a Domestic Supply Chain
October 10, 2022
Arizona, leading the charge towards the green transition
Presas de Relaves: La Prevención de Fallas Catastróficas y los Principios ESG
July 14, 2022
Guillermo Barreda, General Manager, Knight Piésold Peru
Driving Change: The responsible sourcing of cobalt and other key materials for the EV industry
May 23, 2022
“The low carbon economy will likely require US$50 trillion of investment over the next three decades, making it the biggest purchase order in history.”
Copper Production & Development in Chile
May 02, 2022
Investment and streamlined development is needed to capitalize on a generational opportunity.
The Battery Material Supply Chain
February 15, 2022
How the mining sector will play a pivotal role in determining the world's climate change and green revolution outcomes.
Industry Thoughts on Battery Metals
February 15, 2022
Ontario’s battery metal juniors share their opinions.
Sustainability in Mining
August 06, 2021
More than a buzzword, ESG has become the overarching theme impacting all facets of mining.
The Global Tailings Standard
April 16, 2021
The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
